Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Hanuš, S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D. Shalev, I. Kustanovich, R. Mechoulam (2001)
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptorProceedings of the National Academy of Sciences of the United States of America, 98
L. Matsuda, S. Lolait, M. Brownstein, A. Young, T. Bonner (1990)
Structure of a cannabinoid receptor and functional expression of the cloned cDNANature, 346
L. Petrocellis, T. Bisogno, John Davis, R. Pertwee, V. Marzo (2000)
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activityFEBS Letters, 483
C. Hillard, D. Wilkison, W. Edgemond, William Campbell (1995)
Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain.Biochimica et biophysica acta, 1257 3
S. Muthian, K. Nithipatikom, W. Campbell, C. Hillard (2000)
Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier.The Journal of pharmacology and experimental therapeutics, 293 1
D. Piomelli, M. Beltramo, S. Glasnapp, S. Lin, A. Goutopoulos, Xiang-Qun Xie, A. Makriyannis (1999)
Structural determinants for recognition and translocation by the anandamide transporter.Proceedings of the National Academy of Sciences of the United States of America, 96 10
T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, K. Waku (1995)
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.Biochemical and biophysical research communications, 215 1
M. López-Rodríguez, A. Viso, S. Ortega‐Gutiérrez, C. Fowler, G. Tiger, Eva Lago, J. Fernández-Ruiz, J. Ramos (2003)
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.Journal of medicinal chemistry, 46 8
W. Devane, L. Hanuš, A. Breuer, R. Pertwee, L. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam (1992)
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.Science, 258 5090
M. Beltramo, F. Fonseca, M. Navarro, A. Calignano, M. Gorriti, G. Grammatikopoulos, A. Sadile, A. Giuffrida, D. Piomelli (2000)
Reversal of Dopamine D2 Receptor Responses by an Anandamide Transport InhibitorThe Journal of Neuroscience, 20
(2003)
Uptake of the endogenous cannabinoid anandamide by endocytic processes and accumulation in lipid rafts
B. Basavarajappa, M. Saito, T. Cooper, B. Hungund (2003)
Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons.European journal of pharmacology, 466 1-2
H. Schmid (2000)
Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively?Chemistry and physics of lipids, 108 1-2
S. González, J. Romero, R. Miguel, I. Lastres-Becker, M. Villanúa, A. Makriyannis, J. Ramos, J. Fernández-Ruiz (1999)
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.Life sciences, 65 3
T. Bisogno, S. Maurelli, D. Melck, L. Petrocellis, V. Marzo (1997)
Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes*The Journal of Biological Chemistry, 272
S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo, D. Piomelli (2003)
Modulation of anxiety through blockade of anandamide hydrolysisNature Medicine, 9
A. Calignano, G. Rana, Massimiliano Beltramo, Alexandros Makriyannis, D. Piomelli (1997)
Potentiation of anandamide hypotension by the transport inhibitor, AM404.European journal of pharmacology, 337 1
M. López-Rodríguez, A. Viso, S. Ortega‐Gutiérrez, C. Fowler, G. Tiger, Eva Lago, J. Fernández-Ruiz, J. Ramos (2003)
Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.European journal of medicinal chemistry, 38 4
P. Zygmunt, H. Chuang, P. Movahed, D. Julius, E. Högestätt (2000)
The anandamide transport inhibitor AM404 activates vanilloid receptors.European journal of pharmacology, 396 1
Theresa Day, F. Rakhshan, D. Deutsch, E. Barker (2001)
Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide.Molecular pharmacology, 59 6
C. Hillard, A. Jarrahian (2000)
The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes.Chemistry and physics of lipids, 108 1-2
B. Cravatt, Dan Giang, S. Mayfield, D. Boger, R. Lerner, N. Gilula (1996)
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amidesNature, 384
M. Beltramo, N. Stella, A. Calignano, S. Lin, A. Makriyannis, D. Piomelli (1997)
Functional role of high-affinity anandamide transport, as revealed by selective inhibition.Science, 277 5329
W. Stremmel, J. Pohl, A. Ring, T. Herrmann (2001)
A new concept of cellular uptake and intracellular trafficking of long-chain fatty acidsLipids, 36
T. Freund, I. Katona, D. Piomelli (2003)
Role of endogenous cannabinoids in synaptic signaling.Physiological reviews, 83 3
V. Marzo, G. Griffin, L. Petrocellis, I. Brandi, T. Bisogno, W. Williams, Mark Grier, Sanjitha Kulasegram, A. Mahadevan, R. Razdan, B. Martin (2002)
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.The Journal of pharmacology and experimental therapeutics, 300 3
A. Giuffrida, F. Fonseca, F. Nava, Patrick Loubet-Lescoulié, D. Piomelli (2000)
Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.European journal of pharmacology, 408 2
MACCARRONE (2002)
Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activationBlood, 100
A. Giuffrida, M. Beltramo, D. Piomelli (2001)
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.The Journal of pharmacology and experimental therapeutics, 298 1
C. Hillard, W. Edgemond, A. Jarrahian, W. Campbell (1997)
Accumulation of N‐Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated DiffusionJournal of Neurochemistry, 69
C. Hillard (2000)
Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.Prostaglandins & other lipid mediators, 61 1-2
D. Deutsch, R. Omeir, G. Arreaza, D. Salehani, G. Prestwich, Zheng Huang, A. Howlett (1997)
Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase.Biochemical pharmacology, 53 3
F. Rakhshan, Theresa Day, Randy Blakely, Eric Barker (2000)
Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.The Journal of pharmacology and experimental therapeutics, 292 3
A. Jarrahian, S. Manna, W. Edgemond, W. Campbell, C. Hillard (2000)
Structure—Activity Relationships Among N‐Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide TransporterJournal of Neurochemistry, 74
M. Maccarrone, M. Stelt, A. Rossi, G. Veldink, J. Vliegenthart, A. Agrò (1998)
Anandamide Hydrolysis by Human Cells in Culture and Brain*The Journal of Biological Chemistry, 273
BELTRAMO (2000)
Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerolNeuroreport, 11
D. Deutsch, S. Chin (1993)
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.Biochemical pharmacology, 46 5
A. Lichtman, E. Hawkins, G. Griffin, B. Cravatt (2002)
Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.The Journal of pharmacology and experimental therapeutics, 302 1
N. Ueda, R. Puffenbarger, Shozo Yamamoto, D. Deutsch (2000)
The fatty acid amide hydrolase (FAAH).Prostaglandins, leukotrienes, and essential fatty acids, 66 2-3
M. Maccarrone, M. Bari, T. Lorenzon, T. Bisogno, V. Marzo, A. Finazzi-Agrò (2000)
Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide*The Journal of Biological Chemistry, 275
T. Sugiura, K. Waku (2000)
2-Arachidonoylglycerol and the cannabinoid receptors.Chemistry and physics of lipids, 108 1-2
Gregory Gerdeman, J. Ronesi, D. Lovinger (2002)
Postsynaptic endocannabinoid release is critical to long-term depression in the striatumNature Neuroscience, 5
D. Deutsch, S. Glaser, J. Howell, Jeffrey Kunz, R. Puffenbarger, C. Hillard, N. Abumrad (2001)
The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase*The Journal of Biological Chemistry, 276
M. Maccarrone, L. Fiorucci, F. Erba, M. Bari, A. Finazzi-Agrò, F. Ascoli (2000)
Human mast cells take up and hydrolyze anandamide under the control of 5‐lipoxygenase and do not express cannabinoid receptorsFEBS Letters, 468
V. Marzo, T. Bisogno, D. Melck, R. Ross, Heather Brockie, L. Stevenson, R. Pertwee, L. Petrocellis (1998)
Interactions between synthetic vanilloids and the endogenous cannabinoid systemFEBS Letters, 436
M. Maccarrone, M. Attinà, M. Bari, A. Cartoni, C. Ledent, A. Finazzi-Agrò (2001)
Anandamide degradation and N‐acylethanolamines level in wild‐type and CB1 cannabinoid receptor knockout mice of different agesJournal of Neurochemistry, 78
P. Gubellini, B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, G. Bernardi, A. Finazzi-Agrò, M. Maccarrone (2002)
Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic TransmissionThe Journal of Neuroscience, 22
S. Glaser, N. Abumrad, Folayan Fatade, M. Kaczocha, K. Studholme, D. Deutsch (2003)
Evidence against the presence of an anandamide transporterProceedings of the National Academy of Sciences of the United States of America, 100
Thien Dinh, D. Carpenter, F. Leslie, T. Freund, I. Katona, S. Sensi, S. Kathuria, D. Piomelli (2002)
Brain monoglyceride lipase participating in endocannabinoid inactivationProceedings of the National Academy of Sciences of the United States of America, 99
V. Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J. Schwartz, D. Piomelli (1994)
Formation and inactivation of endogenous cannabinoid anandamide in central neuronsNature, 372
F. Fezza, T. Bisogno, Alberto Minassi, G. Appendino, R. Mechoulam, V. Marzo (2002)
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissuesFEBS Letters, 513
D. Dvorak (1989)
Human Mast CellsAdvances in anatomy, embryology, and cell biology, 114
T. Bisogno, M. Maccarrone, L. Petrocellis, A. Jarrahian, A. Finazzi-Agrò, C. Hillard, V. Marzo (2001)
The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors.European journal of biochemistry, 268 7
A. Porter, J. Sauer, M. Knierman, G. Becker, M. Berna, J. Bao, G. Nomikos, Petra Carter, F. Bymaster, Andrea Leese, C. Felder (2002)
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.The Journal of pharmacology and experimental therapeutics, 301 3
M. Beltramo, D. Piomelli
NEUROPHARMACOLOGY: Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol
The endocannabinoids N‐arachidonylethanolamine (AEA or anandamide) and 2‐arachidonylglycerol (2‐AG) are hypothesized to function in the brain as interneuronal signaling molecules. Prevailing models of the actions of these molecules require that they traverse cellular plasma membranes twice; first, following cellular synthesis and second, prior to enzymatic hydrolysis. The transmembrane movement of AEA has been studied in multiple laboratories with a primary focus on its cellular accumulation following extracellular administration. Although there are areas of consensus among laboratories regarding AEA accumulation, several aspects are very unclear. In particular, there is a lack of consensus in the literature regarding the importance of AEA hydrolysis by fatty acid amide hydrolase in maintaining the driving force for accumulation. Furthermore, evidence for and against a transmembrane carrier protein has been published. We have reviewed the available literature and present a working model of the processes that are involved in the cellular accumulation of AEA. It is our hypothesis that transmembrane movement of AEA is regulated by concentration gradient between extracellular and intracellular free AEA. Furthermore, it is our view that a significant portion of the intracellular AEA in most cells is sequestered either by a protein or lipid compartment and that AEA sequestered in this manner does not equilibrate directly with the extracellular pool. Finally, we discuss the available data that have been presented in support of a transmembrane carrier protein for AEA. British Journal of Pharmacology (2003) 140, 802–808. doi:10.1038/sj.bjp.0705468
British Journal of Pharmacology – Wiley
Published: Nov 1, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.